Abstract
A topological substructural molecular design approach (TOPS-MODE) has been used to formulate structural rules for binding of substrates of P-glycoprotein (P-gp). We first review some of the models developed in the recent literature for predicting binding to Pgp. Then, we develop a model using TOPS-MODE, which is able to identify 88.4% of substrates and 84.2% of non-substrates. When the model is presented to an external prediction set of 100 substrates and 77 nonsubstrates it identifies correctly 81.8% of all cases. Using TOPS-MODE strategy we found structural contributions for binding to P-gp, which identifies 24 structural fragments responsible for such binding. We then carried out a chemico-biological analysis of some of the structural fragments found as contributing to P-gp binding of substrates. We show that in general the model developed so far can be used as a virtual screening method for identifying substrates of P-gp from large libraries of compounds.
Keywords: TOPS-MODE, knowledge generation, P-glycoprotein, QSAR, molecular modeling, Spectral Moments, graph-theory descriptors, DEREK, TOPKAT, natural detoxification system, (MDRR), linear discriminant analysis (LDA), Automated Rule-Extraction, Randi, ’, s method, biophore, TSET, PSET, P-gp Efflux, MULTICASE, orthogonalization
Current Pharmaceutical Design
Title: Structural Contributions of Substrates to their Binding to P-Glycoprotein. A TOPSMODE Approach
Volume: 16 Issue: 24
Author(s): Ernesto Estrada, Enrique Molina, Delvin Nodarse and Eugenio Uriarte
Affiliation:
Keywords: TOPS-MODE, knowledge generation, P-glycoprotein, QSAR, molecular modeling, Spectral Moments, graph-theory descriptors, DEREK, TOPKAT, natural detoxification system, (MDRR), linear discriminant analysis (LDA), Automated Rule-Extraction, Randi, ’, s method, biophore, TSET, PSET, P-gp Efflux, MULTICASE, orthogonalization
Abstract: A topological substructural molecular design approach (TOPS-MODE) has been used to formulate structural rules for binding of substrates of P-glycoprotein (P-gp). We first review some of the models developed in the recent literature for predicting binding to Pgp. Then, we develop a model using TOPS-MODE, which is able to identify 88.4% of substrates and 84.2% of non-substrates. When the model is presented to an external prediction set of 100 substrates and 77 nonsubstrates it identifies correctly 81.8% of all cases. Using TOPS-MODE strategy we found structural contributions for binding to P-gp, which identifies 24 structural fragments responsible for such binding. We then carried out a chemico-biological analysis of some of the structural fragments found as contributing to P-gp binding of substrates. We show that in general the model developed so far can be used as a virtual screening method for identifying substrates of P-gp from large libraries of compounds.
Export Options
About this article
Cite this article as:
Estrada Ernesto, Molina Enrique, Nodarse Delvin and Uriarte Eugenio, Structural Contributions of Substrates to their Binding to P-Glycoprotein. A TOPSMODE Approach, Current Pharmaceutical Design 2010; 16 (24) . https://dx.doi.org/10.2174/138161210792389243
DOI https://dx.doi.org/10.2174/138161210792389243 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Immunotoxins and Neuropeptide-Toxin Conjugates Experimental Applications
Mini-Reviews in Medicinal Chemistry The CLCA Gene Family A Novel Family of Putative Chloride Channels
Current Genomics Charge Deficient Analogues of the Natural Polyamines
Current Pharmaceutical Design Structure-Activity Relationships of Glutamate Carboxypeptidase II (GCPII) Inhibitors
Current Medicinal Chemistry Control of Autoimmune Diseases by the B7-CD28 Family Molecules
Current Pharmaceutical Design Strategies for Developing Tuberculosis Vaccines: Emerging Approaches
Current Drug Targets The Tumor Suppressor p53 Regulates c-Maf and Prox-1 to Control Lens Differentiation
Current Molecular Medicine Flow Chemistry to Control the Synthesis of Nano and Microparticles for Biomedical Applications
Current Topics in Medicinal Chemistry Bamboo a Supplement to Human Health: A Comprehensive Review on its Ethnopharmacology, Phytochemistry, and Pharmacological Activity
The Natural Products Journal Patient Perspectives in OMERACT Provide an Anchor for Future Metric Development and Improved Approaches to Healthcare Delivery in Connective Tissue Disease Related Interstitial Lung Disease (CTD-ILD)
Current Respiratory Medicine Reviews Differentiation Between Osteoporotic and Neoplastic Vertebral Fractures: State of The Art and Future Perspectives
Current Medical Imaging A Machine Learning-based Diagnosis of Thyroid Cancer Using Thyroid Nodules Ultrasound Images
Current Bioinformatics The Effect of Pyrroloquinoline Quinone on Apoptosis and Autophagy in Traumatic Brain Injury
CNS & Neurological Disorders - Drug Targets Semaphorins at the Interface of Development and Cancer
Current Drug Targets Beyond the Direct Activation of Cannabinoid Receptors: New Strategies to Modulate the Endocannabinoid System in CNS-Related Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Stem cells contributing to postnatal skeletogenesis in the mouse bone marrow
Current Stem Cell Research & Therapy Adaptor Protein 3BP2 and Cherubism
Current Medicinal Chemistry Clinical Trials of Targeted Alpha Therapy for Cancer
Reviews on Recent Clinical Trials Zinc and its Specific Transporters as Potential Targets in Airway Disease
Current Drug Targets Gene Therapy for Gastric Diseases
Current Gene Therapy